Target intelligence / Profile preview

Staphylococcus aureus tyrosyl-tRNA synthetase (TyrRS or tyrS)

Target
TyrRS or tyrS
Molecular classification
Enzyme, Aminoacyl-tRNA synthetase, Ligase (specifically, EC 6.1.1.1: joining L-tyrosine and tRNA(Tyr)), Class I Aminoacyl-tRNA synthetase
01

Overview

Staphylococcus aureus tyrosyl-tRNA synthetase is an essential bacterial enzyme responsible for linking L-tyrosine to its corresponding tRNA(Tyr) through an ATP-dependent reaction, forming tyrosyl-AMP and subsequently transferring the amino acid to tRNA. This process is fundamental for ribosomal translation and bacterial protein synthesis. TyrRS belongs to the class I aminoacyl-tRNA synthetases, featuring a Rossmann-fold catalytic domain. It has been structurally characterized in complex with several classes of inhibitors, which provided key insights for the development of novel antibiotics. Selective inhibitors of Staphylococcus aureus TyrRS show potent bacteriostatic effects by halting protein synthesis, positioning the enzyme as a promising target in efforts to combat antibiotic resistance in S. aureus infections.

Other names
Tyrosine--tRNA ligaseTyrRStyrS gene product
02

Mechanism of action

Inhibition of tyrosyl-tRNA synthetase blocks aminoacylation of tRNA(Tyr), halting protein synthesis and thus bacterial growth. Most inhibitors are competitive, binding at or near the active site or substrate-binding domain.

03

Biological functions

Protein synthesis — Catalyzes the attachment of tyrosine to its cognate tRNA(Tyr), a critical step in ribosomal translationAminoacylation — Ensures accurate translation of genetic code by charging tRNA with the correct amino acidCell viability — Essential for bacterial survival and proliferation
04

Disease associations

Infection — Essential for viability of Staphylococcus aureus, an important human pathogen. Inhibition leads to bacteriostasis/bactericidal effectsOther — Not directly implicated in non-infectious diseases.
05

Safety considerations

Off-target toxicity in humans is minimized by selectivity for the bacterial enzyme, but there is theoretical risk with aminoacyl-tRNA synthetase inhibitors if not highly specificPotential for rapid resistance emergence via mutation in the tyrS gene should be considered in antibiotic strategy
06

Interacting drugs

SB-219383

6 more in the full profile.

07

Biomarkers

No validated clinical biomarkers specific for TyrRS activity in Staphylococcus aureus; selection is typically based on pathogen identification (e.g., S. aureus culture/diagnosis)Resistance mutations in tyrS may serve as laboratory biomarkers for loss of drug efficacy, but not in routine clinical use.

Beyond the preview

Go deeper on Staphylococcus aureus tyrosyl-tRNA synthetase (TyrRS or tyrS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus aureus tyrosyl-tRNA synthetase (TyrRS or tyrS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call